Advertisement

Neuroscience and Behavioral Physiology

, Volume 49, Issue 2, pp 259–265 | Cite as

Treatment of Speech Development Disorders in Preschool Children

  • V. F. ShalimovEmail author
  • N. Yu. Suvorinova
  • Yu. E. Nesterovsky
Article
  • 9 Downloads

Objectives. To study the efficacy of Neuroferon in general speech development disorders (SDD). Materials and methods. A total of 30 children of preschool age with SDD were studied; patients were divided into three age groups: 4–5 years (eight patients), 5–6 years (10 patients), and 6–7 years (12 patients). Treatment continued for two months: Neuroferon was given at a dose of one tablet three times a day. Multifaceted psychological investigations of speech disorders were performed using a number of methods. These data were evaluated with consideration of overall mental state and the children’s emotional and behavioral characteristics. Results and conclusions. Neuroferon was found to have therapeutic actions in SDD in children (increases in the level of audioverbal memory, improvements in expressive speech, phonematic perception, and articular motor function, and increases in vocabulary and the production of connected speech, etc.), which were accompanied by decreases in anxiety, hyperactivity, and attention deficit. Use of Neuroferon was shown to be safe for children. The authors regard these results as preliminary.

Keywords

speech development disorders general speech development disorders treatment Neuroferon 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    A. N. Kornev, Fundamentals of Speech Pathology of Childhood: Clinical and Psychological Aspects, Rech, St. Petersburg (2006).Google Scholar
  2. 2.
    R. E. Levina, “Differentiation of speech development anomalies in children,” Defektologiya, No. 2, 12–16 (1975).Google Scholar
  3. 3.
    N. J. Cohen, D. D. Vallance, and M. Darwick, “The interface between ADHD and language impairment: An examination of language, achievement, and cognitive processing,” J. Child Psychol. Psychiatry, 41, 353–362 (2000).CrossRefPubMedGoogle Scholar
  4. 4.
    N. N. Zavadenko, “Speech development disorders in children: early diagnosis and therapy,” Zh. Nevrol. Psikhiat., 116, No. 12, 119–125 (2016),  https://doi.org/10.17116/jnevro2016116121119-125.CrossRefGoogle Scholar
  5. 5.
    D. V. M. Bishop, “Motor immaturity and specific language impairment: Evidence for a common genetic basis,” Am. J. Med. Genet., 114, 110 (2001).Google Scholar
  6. 6.
    A. M. Livinskaya, Disorders of Speech Development in Children with Attention Deficit Hyperactivity Disorder: Dissertation for Master’s Degree in Medical Sciences, St. Petersburg (2007).Google Scholar
  7. 7.
    O. A. Bezrukova and O. N. Kalenkova, A Method for Determining the Level of Speech Development in Preschool Children, Moscow (2008), pp. 245–251.Google Scholar
  8. 8.
    V. F. Shalimov, E. V. Makushkin, and G. R. Novikova, “Experience in the use of Tenoten pediatric in children with delayed psychological development,” Doktor Ru, 4, 46–48 (2009).Google Scholar
  9. 9.
    V. F. Shalimov and Yu. N. Nesterovskii, “Experience in the use of Tenoten pediatric in children with delayed psychological development of organic cerebral origin,” Effektiv. Farmakol., 2, 56–63 (2012).Google Scholar
  10. 10.
    L. Pereira, R. Medina, M. Baena, et al., “IFN gamma regulates proliferation and neuronal differentiation by STAT1 in adult SVZ niche,” Front. Cell. Neurosci., 9 (2015),  https://doi.org/10.3389/fncel.2015.00270.
  11. 11.
    C. T. Ekdahl, J.-H. Claasen, S. Bonde, et al., “Inflammation is detrimental for neurogenesis in adult brain,” Proc. Natl. Acad. Sci. USA, 100, No. 23, 13632–13637 (2003),  https://doi.org/10.1073/pnas.2234031100.CrossRefPubMedGoogle Scholar
  12. 12.
    A. C. Campos, G. N. Vaz, V. M. Saito, and A. L. Teixeira, “Further evidence for the role of interferon-gamma on anxiety- and depressive-like behaviors: involvement of hippocampal neurogenesis and NGF production,” Neurosci. Lett., 578, 100–105 (2014),  https://doi.org/10.1016/j.neulet.2014.06.039.CrossRefPubMedGoogle Scholar
  13. 13.
    R. De Simone, G. Levi, and F. Aloisi, “Interferon gamma gene expression in rat central nervous system glial cells,” Cytokine, 10, No. 6, 418–422 (1998),  https://doi.org/10.1006/cyto.1997.0314.CrossRefPubMedGoogle Scholar
  14. 14.
    K. N. Fantetti, E. L. Gray, P. Ganesan, et al., “Interferon gamma protects neonatal neural stem/progenitor cells during measles virus infection of the brain,” J. Neuroinflammation, 13, No. 1, 107 (2016),  https://doi.org/10.1186/s12974-016-0571-1.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • V. F. Shalimov
    • 1
    Email author
  • N. Yu. Suvorinova
    • 2
  • Yu. E. Nesterovsky
    • 2
  1. 1.Serbskii Federal Medical Research Center for Psychiatry and NarcologyRussian Ministry of HealthMoscowRussia
  2. 2.Pirogov Russian National Research Medical UniversityRussian Ministry of HealthMoscowRussia

Personalised recommendations